AcelRx Pharmaceuticals (ACRX) Set to Announce Quarterly Earnings on Thursday

AcelRx Pharmaceuticals (NASDAQ:ACRXGet Rating) will issue its quarterly earnings data after the market closes on Thursday, August 11th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

AcelRx Pharmaceuticals (NASDAQ:ACRXGet Rating) last posted its earnings results on Monday, May 16th. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of ($0.06). The business had revenue of $0.44 million for the quarter, compared to the consensus estimate of $0.50 million. During the same quarter in the prior year, the firm posted ($0.08) earnings per share. On average, analysts expect AcelRx Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AcelRx Pharmaceuticals Trading Up 2.4 %

ACRX stock opened at $0.22 on Thursday. The business’s 50-day moving average price is $0.23 and its two-hundred day moving average price is $0.30. The firm has a market cap of $32.69 million, a PE ratio of -0.82 and a beta of 0.44. AcelRx Pharmaceuticals has a 1-year low of $0.16 and a 1-year high of $1.25.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on AcelRx Pharmaceuticals in a report on Monday. They issued a “sell” rating on the stock.

About AcelRx Pharmaceuticals

(Get Rating)

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures.

See Also

Earnings History for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.